How grave they might be remains unknown, but regulatory questions have surfaced in briefing documents related to the soon-to-happen panel meeting on Sarepta Therapeutics Inc.’s gene transfer therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results